HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Optimal adrenergic support in septic shock due to peritonitis.

AbstractBACKGROUND:
The authors evaluated optimal adrenergic support using norepinephrine, dopamine, and dobutamine in a clinically relevant model of septic shock.
METHODS:
Twenty-eight mature, female, anesthetized sheep (weight, 30.5 +/- 3.6 kg) underwent cecal ligation and perforation and were randomized into four groups of seven animals to be treated with norepinephrine, dopamine-norepinephrine, dobutamine-norepinephrine, or no adrenergic agent. In all groups, lactated Ringer's solution was administered to restore cardiac filling pressures to baseline. In the norepinephrine group, norepinephrine (0.5-5 microg. kg(-1). min(-1)) was titrated to maintain mean arterial pressure between 75-85 mmHg. In the dopamine-norepinephrine group, dopamine was given first, and norepinephrine was added only when mean arterial pressure remained below 75 mmHg despite the infusion of 20 microg. kg(-1). min(-1) dopamine. In the dobutamine-norepinephrine group, dobutamine was started at the same time as norepinephrine and titrated up to 20 microg. kg(-1). min(-1) to get a 15% increase in cardiac output.
RESULTS:
The dobutamine-norepinephrine group had greater cardiac output; superior mesenteric blood flow, oxygen delivery (Do(2)), and oxygen consumption ([OV0312]o(2)); and lower blood lactate concentration and partial pressure of carbon dioxide (Pco(2)) gap than the controls did. Cumulative urine output was significantly higher in the dobutamine-norepinephrine group than in the other groups. Survival time was significantly longer in the dobutamine-norepinephrine (24 +/- 4 h), dopamine- norepinephrine (24 +/- 6 h), and norepinephrine (20 +/- 1 h) groups than the control group (17 +/- 2 h; P < 0.05 vs. other groups), and significantly longer in the combined dopamine-norepinephrine and dobutamine-norepinephrine groups (24 +/- 5 h) than in the norepinephrine alone group (P < 0.05). Histologic examination of lung biopsies revealed less severe lesions in the dobutamine-norepinephrine group than in the control and norepinephrine alone groups. Anatomic alterations in the lung, liver, and small intestine were less severe in the dobutamine-norepinephrine group than in the other groups.
CONCLUSIONS:
In this prolonged septic shock model, association of norepinephrine with either dopamine or dobutamine resulted in the longest survival and the least severe pulmonary lesions. The combination of dobutamine with norepinephrine was associated with a better myocardial performance, greater Do(2) and [OV0312]o(2), lower blood lactate concentration and Pco(2) gap, and less anatomic injury.
AuthorsQinghua Sun, Zizhi Tu, Suzana Lobo, George Dimopoulos, Nathalie Nagy, Peter Rogiers, Daniel De Backer, Jean-Louis Vincent
JournalAnesthesiology (Anesthesiology) Vol. 98 Issue 4 Pg. 888-96 (Apr 2003) ISSN: 0003-3022 [Print] United States
PMID12657850 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenergic Agents
  • Cardiotonic Agents
  • Sympathomimetics
  • Lactic Acid
  • Dobutamine
  • Dopamine
  • Norepinephrine
Topics
  • Adrenergic Agents (therapeutic use)
  • Animals
  • Body Temperature (drug effects)
  • Cardiotonic Agents (therapeutic use)
  • Dobutamine (therapeutic use)
  • Dopamine (therapeutic use)
  • Female
  • Hemodynamics (drug effects)
  • Lactic Acid (blood)
  • Norepinephrine (therapeutic use)
  • Oxygen Consumption (drug effects)
  • Peritonitis (complications)
  • Regional Blood Flow (drug effects, physiology)
  • Respiratory Mechanics (drug effects)
  • Sheep
  • Shock, Septic (drug therapy, etiology, physiopathology)
  • Survival Analysis
  • Sympathomimetics (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: